Tri-complex of Daraxonrasib (RMC-6236), KRAS G12C, and CypA

Tri-complex of Daraxonrasib (RMC-6236), KRAS G12C, and CypA Descriptor: (1R,2S)-N-[(1P,7S,9S,13R,20M)-21-ethyl-20-{2-[(1R)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)pyridin-3-yl}-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetraazapentacyclo[17.5.2.1~2,5~.1~9,13~.0~22,26~]octacosa-1(24),2,5(28),19,22,25-hexaen-7-yl]-2-methylcyclopropane-1-carboxamide, GTPase KRas, MAGNESIUM ION, ... Authors: Chen, A, Tomlinson, A.C.A, Bieder, R, Knox, J.E, Yano, J.K. Deposit date: 2024-04-18 Release date: 2025-03-19 Last modified: 2025-04-09 Method: X-RAY DIFFRACTION (1.41 Å) Cite: Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. J.Med.Chem., 68, 2025